Standout Papers

Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a r... 2018 2026 2020 2023 272
  1. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial (2018)
    Noel W. Clarke, Paweł Wiechno et al. The Lancet Oncology

Citation Impact

57 standout
Sub-graph 1 of 21

Citing Papers

New clinical trial design in precision medicine: discovery, development and direction
2024 Standout
ADMETlab 3.0: an updated comprehensive online ADMET prediction platform enhanced with broader coverage, improved performance, API functionality and decision support
2024 Standout
1 intermediate paper

Works of Maria Learoyd being referenced

In vitro evaluation of the inhibition and induction potential of olaparib, a potent poly(ADP-ribose) polymerase inhibitor, on cytochrome P450
2017
Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors
2013

Author Peers

Author Oncology Molecular Biology Pharmacology PRM Last Decade Papers Cites
Maria Learoyd 548 354 157 284 25 980
Gus Shaver 25 2 34 1.8k
Syuichi Takano 149 759 26 29 16 1.0k
Yuejü Cui 2 33 431
Hyungmin Ahn 9 32 2 16 1.0k
Shinya Takami 306 348 48 14 20 1.2k

All Works

Loading papers...

Rankless by CCL
2026